GlassScriptPhysician profile
Karen L Samples
NPI 1972759348
$3,121.43
in general payments reported to CMS, 2019-2025
34 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $291 · 2021: $375 · 2022: $636 · 2023: $600 · 2024: $438 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.79 |
| Education | $187.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $939.36 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $340.12 | 2019-2023 | |
| Abbvie INC. | $304.70 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Novo Nordisk INC | $247.54 | 2019-2024 | Wegovy |
| Channel Medsystems, INC. | $168.58 | 2022-2023 | |
| Exeltis, USA INC. | $108.96 | 2019-2022 | |
| Aspira Women'S Health INC | $106.79 | 2023 | Ova1 |
| Myovant Sciences INC. | $81.73 | 2021-2022 | |
| Intuitive Surgical, INC. | $78.47 | 2021-2024 | |
| Dysis Medical, INC. | $54.84 | 2019 | |
| Sumitomo Pharma America, INC. | $51.85 | 2023-2025 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $47.95 | 2019-2025 | |
| Sage Therapeutics, LLC | $46.42 | 2025 | Zurzuvae |
| Amgen INC. | $42.10 | 2020-2022 | |
| Meditrina | $41.19 | 2023-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $41.08 | 2022-2025 | Nexplanon |
| Smith+Nephew, INC. | $39.44 | 2019-2022 | |
| Boston Scientific Corporation | $38.64 | 2024 | Solyx Sis System |
| Daiichi Sankyo INC. | $34.73 | 2019-2020 | |
| Scynexis, INC. | $34.30 | 2022 | |
| Mayne Pharma Commercial LLC | $32.55 | 2021-2022 | |
| Becton, Dickinson and Company | $30.04 | 2022 | |
| Hologic Sales and Service, LLC | $27.84 | 2019-2023 | Myosure Tissue Removal Device |
| Minerva Surgical, INC | $25.99 | 2019-2024 | |
| Mylan Pharmaceuticals INC. | $24.44 | 2019-2021 | |
| Coopersurgical, INC. | $20.51 | 2019 | |
| Convatec INC. | $18.88 | 2022 | |
| Shield Therapeutics INC | $17.85 | 2023 | Accrufer |
| Millicent US INC | $16.11 | 2025 | Femlyv |
| Amag Pharmaceuticals, INC. | $12.48 | 2019 | |
| Merck Sharp & Dohme LLC | $12.28 | 2019 | |
| Avion Pharmaceuticals | $11.28 | 2019 | |
| Evofem Biosciences, INC. | $11.28 | 2021 | |
| Lupin INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Samples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.